Ferric carboxymaltose - Vifor

Drug Profile

Ferric carboxymaltose - Vifor

Alternative Names: Ferinject; Injectafer; Iron-dextri-maltose; Iroprem; Renegy; VIT-45; Z-213

Latest Information Update: 24 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vifor
  • Developer Luitpold Pharmaceuticals; Vifor; Zeria
  • Class Antianaemics; Heavy metals; Iron compounds
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase III Chronic heart failure; Restless legs syndrome

Most Recent Events

  • 03 Jul 2018 Phase-III clinical trials in Iron deficiency anaemia in China (IV) (NCT03591406)
  • 14 May 2018 Luitpold Pharmaceuticals plans a phase III trial for Iron Deficiency Anaemia in May 2018 , (NCT03523117)
  • 11 May 2018 Preregistration for Iron deficiency anaemia in Japan (IV) before May 2018 (Zeria pipeline, June 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top